NO20074421L - Nukleinsyrekonstrukter - Google Patents

Nukleinsyrekonstrukter

Info

Publication number
NO20074421L
NO20074421L NO20074421A NO20074421A NO20074421L NO 20074421 L NO20074421 L NO 20074421L NO 20074421 A NO20074421 A NO 20074421A NO 20074421 A NO20074421 A NO 20074421A NO 20074421 L NO20074421 L NO 20074421L
Authority
NO
Norway
Prior art keywords
hcmv
immediate early
promoter sequence
chimeric promoter
exon
Prior art date
Application number
NO20074421A
Other languages
English (en)
Inventor
James Fuller
Original Assignee
Powderjet Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderjet Vaccines Inc filed Critical Powderjet Vaccines Inc
Publication of NO20074421L publication Critical patent/NO20074421L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Et nukleinsyrekonstrukt omfattende en kimær promotersekvens og et kloningssete for innsetting av en kodende sekvens i funksjonsdyktig sammenkobling med den kimære promoter, hvori den kimære promotersekvens omfatter: (a) en umiddelbar tidlig promotersekvens av hCMV; (b) exon 1 og minst en del av exon 2 av det større umiddelbare tidlige gen av hCMV; og (c) et heterologt intron innsatt istedenfor intron A-regionen i det større umiddelbare tidlige gen av hCMV.
NO20074421A 2005-02-01 2007-08-30 Nukleinsyrekonstrukter NO20074421L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64838205P 2005-02-01 2005-02-01
US67249705P 2005-04-19 2005-04-19
GBGB0507997.5A GB0507997D0 (en) 2005-02-01 2005-04-20 Nucleic acid constructs
PCT/GB2006/000344 WO2006082398A2 (en) 2005-02-01 2006-02-01 Nucleic acid constructs

Publications (1)

Publication Number Publication Date
NO20074421L true NO20074421L (no) 2007-10-31

Family

ID=36178086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074421A NO20074421L (no) 2005-02-01 2007-08-30 Nukleinsyrekonstrukter

Country Status (20)

Country Link
US (1) US20100221349A1 (no)
EP (1) EP1850869A2 (no)
JP (1) JP2008528020A (no)
KR (1) KR20070100403A (no)
CN (1) CN101155597A (no)
AP (1) AP2007004137A0 (no)
AU (1) AU2006210716A1 (no)
BR (1) BRPI0607119A2 (no)
CA (1) CA2596731A1 (no)
EA (1) EA011557B1 (no)
GB (1) GB0507997D0 (no)
IL (1) IL184653A0 (no)
MA (1) MA29274B1 (no)
MX (1) MX2007009164A (no)
NI (1) NI200700191A (no)
NO (1) NO20074421L (no)
SG (1) SG158902A1 (no)
TN (1) TNSN07295A1 (no)
WO (1) WO2006082398A2 (no)
ZA (1) ZA200707522B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147430A1 (en) * 2003-10-10 2008-11-28 Powderject Vaccines Inc Nucleic acid constructs
CA2632261A1 (en) * 2005-12-05 2007-06-14 Guava Technologies Particle-based analyte characterization
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2715078C (en) * 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
AU2008331673B2 (en) 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
WO2009092038A1 (en) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
DK2358386T3 (en) 2008-11-28 2017-02-13 Statens Seruminstitut Optimized flu vaccine
ES2759015T3 (es) 2010-02-10 2020-05-07 Mayo Found Medical Education & Res Métodos y materiales para tratar el cáncer
WO2013138697A1 (en) * 2012-03-15 2013-09-19 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN103740715B (zh) * 2013-12-25 2016-03-23 北京大北农科技集团股份有限公司 嵌合启动子及其用途
CN103901209B (zh) * 2014-02-18 2016-05-25 王明丽 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
WO2015143221A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10188713B2 (en) 2014-03-19 2019-01-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN105120042B (zh) * 2015-09-09 2019-02-12 小米科技有限责任公司 移动终端
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20210187064A1 (en) * 2018-05-07 2021-06-24 Administrators Of The Tulane Educational Fund Mutated e. coli enterotoxins as anti-inflammatory agents
WO2022155226A1 (en) * 2021-01-12 2022-07-21 Duke University Compositions and methods for the genetic manipulation of the influenza virus
WO2024097894A1 (en) * 2022-11-04 2024-05-10 RNAimmune, Inc. Compositions and methods of ribonucleic acid vaccines encoding nye-so-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) * 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
NZ279995A (en) * 1994-01-21 1998-04-27 Powderject Vaccines Inc Gas driven gene delivery instrument with a conical exit nozzle and a cartridge with an arcuate, linear passage
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
EP1373524B1 (en) * 2000-10-13 2006-04-12 Chiron Corporation Cytomegalovirus intron a fragments
WO2003004055A2 (en) * 2000-11-27 2003-01-16 Powderject Vaccines, Inc. Nucleic acid adjuvants
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
SG147430A1 (en) * 2003-10-10 2008-11-28 Powderject Vaccines Inc Nucleic acid constructs
AU2004280630A1 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Method

Also Published As

Publication number Publication date
US20100221349A1 (en) 2010-09-02
ZA200707522B (en) 2008-08-27
EA011557B1 (ru) 2009-04-28
EA200701643A1 (ru) 2008-02-28
CA2596731A1 (en) 2006-08-10
BRPI0607119A2 (pt) 2009-08-11
MX2007009164A (es) 2008-03-13
WO2006082398A2 (en) 2006-08-10
AP2007004137A0 (en) 2007-08-31
EP1850869A2 (en) 2007-11-07
NI200700191A (es) 2008-02-05
JP2008528020A (ja) 2008-07-31
CN101155597A (zh) 2008-04-02
GB0507997D0 (en) 2005-05-25
IL184653A0 (en) 2007-12-03
SG158902A1 (en) 2010-02-26
AU2006210716A1 (en) 2006-08-10
WO2006082398A3 (en) 2006-10-19
TNSN07295A1 (en) 2008-12-31
KR20070100403A (ko) 2007-10-10
MA29274B1 (fr) 2008-02-01

Similar Documents

Publication Publication Date Title
NO20074421L (no) Nukleinsyrekonstrukter
NO20062080L (no) Nukleinsyrekonstrukter
MXPA05011795A (es) Evidencia de maiz tc1507 y metodos para deteccion del mismo.
PT1597391E (pt) Utilização de arn intrónico para medir a expressão genética
EA201301069A1 (ru) Событие 5307 кукурузы
MX2007010036A (es) Maiz evento 3272 y metodos para la deteccion del mismo.
EP1771570A4 (en) ADDITION OF TRANSGENES IN ADENOVIRUS VECTORS
PL1941045T3 (pl) Zastosowanie sekwencji kwasu nukleinowego do wytwarzania transgenicznej rośliny o zwiększonej tolerancji na suszę
GB0317466D0 (en) Use
UA97088C2 (ru) Трансгенная кукуруза das-59122-7, стойкая к насекомым, и способы его обнаружения
EP1859046A4 (en) EXPRESSION VECTOR FOR ANIMAL CELL COMPRISING AT LEAST ONE COPY OF MAR MARKER SEQUENCES AT THE 3 'TERMINAL OF THE GENE TRANSCRIPTION TERMINATION REGION AND EXPRESSION TECHNIQUE OF A FOREIGN GENE USING THE SAME
EP1828404A4 (en) DEVICES AND METHODS FOR DETERMINING THE ACTIVITY OF A PROTEASE
EP1477560A4 (en) PROMOTER, INTRON AND TERMINATOR OF ORIGIN ALGALE
MX2021004455A (es) Composiciones y métodos para administrar transgenes.
MX2009006681A (es) Composiciones y metodos para la expresion de acidos nucleicos.
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
UA92913C2 (ru) Экспрессионный вектор и способы продуцирования высоких уровней белков
WO2007046787A3 (en) Methods of reducing repeat-induced silencing of transgene expression and improved fluorescent biosensors
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
WO2003047532A3 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
DE10342670A1 (de) Isoliertes Photoprotein mtClytin, sowie dessen Verwendung
TW200628611A (en) Nucleic acid constructs
MXPA05006983A (es) Promotor artificial para la expresion de secuencias de acido desoxirribonucleico en celulas vegetales.
ATE401399T1 (de) Nukleinsäure für einen klonierungsvektor
DE60130465D1 (de) Mutierte muskelspezifische enhancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application